Video

Dr. Gralla on Chemotherapy-Induced Nausea and Vomiting

Dr. Richard Gralla, from the Quality of Life Research Associates, on Chemotherapy-Induced Nausea and Vomiting.

Richard Gralla, MD, Medical Director, Quality of Life Research Associates, New York City, discusses efforts that have been made to control chemotherapy-induced nausea and vomiting (CINV) while stressing that more advances have been developed that control emesis than nausea.

Progress has been made at managing both nausea and vomiting; however, it has become clear that the two are separate entities. Going back to the basics, textbooks suggest that the symptoms are anorexia, nausea, and vomiting, in that order. These symptoms may share pathways but each appears to have its own individual mechanism as well.

Gralla suggests that inhibiting fewer pathways such as neurokinin 1 (NK1) and serotonin, may help with vomiting or nausea but is not enough. Other pathways may be implicated and still need to be discovered and investigated in trials focusing specifically on nausea.

<<<

View more from the 2012 MASCC Symposium

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School